SynBioBeta 2026
The Era of Programmable Biology
Join Our Community — Register Today
May 4-7
May 4-7
2026
2026
San Jose Convention Center
San Jose Convention Center
California, USA
California, USA
Topic Areas:



AIxBIO
Foundation models & multimodal biological AI
Predictive design for drugs, materials & sustainable systems
Shared data + tooling for programmable biology
More



Human Health & Longevity
AI-powered drug discovery
Cell & gene therapies
Diagnostics & precision medicine
Engineered cells, tissues & therapeutics
More



Planetary Health & Sustainability
Food & Agriculture
Climate Tech & Environment
Chemicals & Materials
Space Exploration
More



Biomanufacturing at Scale
Continuous & precision fermentation
Modular, scalable bioprocesses
Real-time monitoring & control
Cost-competitive, low-carbon production
More



Tools, Tech & Platforms
Sequencing, synthesis, editing
Automation & cloud labs
BioCAD, ELNs & data platforms AI-driven discovery tools
More



Business of Biology
Commercializing biotech products
Scaling markets & go-to-market strategy
Funding, partnerships & investor insights
Regulatory, IP & bioeconomy strategy
More
The world’s premier gathering of biological entrepreneurs, engineers and investors.
Join the SynBioBeta community for three days of visionary talks, deal-making, and hands-on exploration of programmable biology. From AI-designed medicines to sustainable biomanufacturing of chemicals, materials, food, and consumer goods, SynBioBeta brings the global community together to discover the latest technologies, business trends, and partnerships.
Why attend?
AIxBIO Revolution
AI and biology are converging to launch a new era of innovation. From advanced tools and technologies to new therapies, sustainable materials, and resilient food systems, this partnership is reshaping human health, planetary health, and the future of life sciences.
AIxBIO Revolution
AI and biology are converging to launch a new era of innovation. From advanced tools and technologies to new therapies, sustainable materials, and resilient food systems, this partnership is reshaping human health, planetary health, and the future of life sciences.
AIxBIO Revolution
AI and biology are converging to launch a new era of innovation. From advanced tools and technologies to new therapies, sustainable materials, and resilient food systems, this partnership is reshaping human health, planetary health, and the future of life sciences.
Tomorrow’s Tools & Tech
Discover the Tools of Tomorrow: Explore cutting-edge AI models, DNA synthesis, automation platforms, and biomanufacturing breakthroughs in the expo hall.
Tomorrow’s Tools & Tech
Discover the Tools of Tomorrow: Explore cutting-edge AI models, DNA synthesis, automation platforms, and biomanufacturing breakthroughs in the expo hall.
Tomorrow’s Tools & Tech
Discover the Tools of Tomorrow: Explore cutting-edge AI models, DNA synthesis, automation platforms, and biomanufacturing breakthroughs in the expo hall.
Meet High-Value Partners
Meet Your Partners: With structured 1:1 meetings, round tables, and networking receptions, connect directly with investors, Fortune 500 leaders, and the next wave of programmable biology founders.
Meet High-Value Partners
Meet Your Partners: With structured 1:1 meetings, round tables, and networking receptions, connect directly with investors, Fortune 500 leaders, and the next wave of programmable biology founders.
Meet High-Value Partners
Meet Your Partners: With structured 1:1 meetings, round tables, and networking receptions, connect directly with investors, Fortune 500 leaders, and the next wave of programmable biology founders.
Shape the Bioeconomy Conversation
Shape the Conversation: Join panels on policy, funding, and scaling the bioeconomy, alongside government leaders from the NSF, DARPA, ARPA-H, NIH, and beyond.
Shape the Bioeconomy Conversation
Shape the Conversation: Join panels on policy, funding, and scaling the bioeconomy, alongside government leaders from the NSF, DARPA, ARPA-H, NIH, and beyond.
Shape the Bioeconomy Conversation
Shape the Conversation: Join panels on policy, funding, and scaling the bioeconomy, alongside government leaders from the NSF, DARPA, ARPA-H, NIH, and beyond.
Join the SynBio Community
Experience the Community: SynBioBeta is more than a conference—it’s the center of a movement that is making biology programmable.
Join the SynBio Community
Experience the Community: SynBioBeta is more than a conference—it’s the center of a movement that is making biology programmable.
Join the SynBio Community
Experience the Community: SynBioBeta is more than a conference—it’s the center of a movement that is making biology programmable.
Who should attend?
Founders & Bioengineers
Entrepreneurs, Founders, Bioengineers, Scientists scaling biology from lab to market
Founders & Bioengineers
Entrepreneurs, Founders, Bioengineers, Scientists scaling biology from lab to market
Founders & Bioengineers
Entrepreneurs, Founders, Bioengineers, Scientists scaling biology from lab to market
Pharma & Fortune 500 Leaders
Pharma & Fortune 500 Executives looking for new technologies and partners
Pharma & Fortune 500 Leaders
Pharma & Fortune 500 Executives looking for new technologies and partners
Pharma & Fortune 500 Leaders
Pharma & Fortune 500 Executives looking for new technologies and partners
Investors & Policy Makers
Investors & Policy Leaders defining the future of the bioeconomy
Investors & Policy Makers
Investors & Policy Leaders defining the future of the bioeconomy
Investors & Policy Makers
Investors & Policy Leaders defining the future of the bioeconomy
Students & Emerging Innovators
Students & Early Career Innovators eager to connect with pioneers in the field
Students & Emerging Innovators
Students & Early Career Innovators eager to connect with pioneers in the field
Students & Emerging Innovators
Students & Early Career Innovators eager to connect with pioneers in the field
sponsors & Exhibitors
What attendees are saying:





"Every time I attend SynBioBeta, I walk away with something transformative — a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
Alex Carter
Constructive Bio





"A conference not to be missed -- this is the place for SynBio power users, experts, key opinion leaders, investors, vendors, students and novices."
Emily LeProust
Twist Bioscience





"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
Jacob Glanville
Centivax
Sessions will include:
1
May 6, 2026
Genome as Canvas: Composing Life at Scale
"Reading, writing, and editing DNA were just the prelude. The new frontier is composition—designing entire genomes like symphonies, guided by AI models trained on millions of sequences. In this new paradigm, biology becomes a writable medium where genes, circuits, and chromosomes are arranged with intention rather than discovered by chance. From AI-optimized CRISPR systems and compact editors like TIGR to CRISPR SWAPnDROP and Bridge Recombinases capable of megabase-scale rewrites in human cells, a new toolkit is emerging that treats the genome not as a fragile molecule but as an editable architecture. These molecular instruments bypass the cell’s own repair machinery, offering a level of precision and predictability that brings genome design closer to true composition—a craft as deliberate and creative as writing code or composing music.
[…]
1
May 6, 2026
Genome as Canvas: Composing Life at Scale
"Reading, writing, and editing DNA were just the prelude. The new frontier is composition—designing entire genomes like symphonies, guided by AI models trained on millions of sequences. In this new paradigm, biology becomes a writable medium where genes, circuits, and chromosomes are arranged with intention rather than discovered by chance. From AI-optimized CRISPR systems and compact editors like TIGR to CRISPR SWAPnDROP and Bridge Recombinases capable of megabase-scale rewrites in human cells, a new toolkit is emerging that treats the genome not as a fragile molecule but as an editable architecture. These molecular instruments bypass the cell’s own repair machinery, offering a level of precision and predictability that brings genome design closer to true composition—a craft as deliberate and creative as writing code or composing music.
[…]
May 6, 2026
Genome as Canvas: Composing Life at Scale
"Reading, writing, and editing DNA were just the prelude. The new frontier is composition—designing entire genomes like symphonies, guided by AI models trained on millions of sequences. In this new paradigm, biology becomes a writable medium where genes, circuits, and chromosomes are arranged with intention rather than discovered by chance. From AI-optimized CRISPR systems and compact editors like TIGR to CRISPR SWAPnDROP and Bridge Recombinases capable of megabase-scale rewrites in human cells, a new toolkit is emerging that treats the genome not as a fragile molecule but as an editable architecture. These molecular instruments bypass the cell’s own repair machinery, offering a level of precision and predictability that brings genome design closer to true composition—a craft as deliberate and creative as writing code or composing music.
[…]
2
May 6, 2026
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” — turning on only inside diseased cells or under specific physiological conditions. This session explores how neural networks, trained on RNA and protein data, are unlocking programmable therapies with unprecedented precision. Imagine cancer drugs that remain inert until they meet tumor markers, or RNA vaccines that adapt to evolving viral landscapes in real time. The future of medicine isn’t static molecules — it’s intelligent, adaptive therapeutics
[…]
2
May 6, 2026
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” — turning on only inside diseased cells or under specific physiological conditions. This session explores how neural networks, trained on RNA and protein data, are unlocking programmable therapies with unprecedented precision. Imagine cancer drugs that remain inert until they meet tumor markers, or RNA vaccines that adapt to evolving viral landscapes in real time. The future of medicine isn’t static molecules — it’s intelligent, adaptive therapeutics
[…]
May 6, 2026
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” — turning on only inside diseased cells or under specific physiological conditions. This session explores how neural networks, trained on RNA and protein data, are unlocking programmable therapies with unprecedented precision. Imagine cancer drugs that remain inert until they meet tumor markers, or RNA vaccines that adapt to evolving viral landscapes in real time. The future of medicine isn’t static molecules — it’s intelligent, adaptive therapeutics
[…]
3
May 5, 2026
Bio500: How the World's Biggest Companies are Transforming Their Value Chains with Biotech.
Fortune 500 companies are turning to synthetic biology to drive efficiency, resilience, and sustainability across their value chains. By integrating biotech, they can reduce reliance on scarce resources, accelerate product innovation, and respond to shifting consumer and regulatory demands. This session brings together leaders from global companies to share how biology is reshaping sourcing, production, and product portfolios. Attendees will gain insights into strategic approaches, cross-industry collaboration, and the investments enabling large-scale transformation, providing a glimpse into how the world’s largest companies are leveraging biotech to stay competitive, meet sustainability goals, and shape the future of industry.
[…]
3
May 5, 2026
Bio500: How the World's Biggest Companies are Transforming Their Value Chains with Biotech.
Fortune 500 companies are turning to synthetic biology to drive efficiency, resilience, and sustainability across their value chains. By integrating biotech, they can reduce reliance on scarce resources, accelerate product innovation, and respond to shifting consumer and regulatory demands. This session brings together leaders from global companies to share how biology is reshaping sourcing, production, and product portfolios. Attendees will gain insights into strategic approaches, cross-industry collaboration, and the investments enabling large-scale transformation, providing a glimpse into how the world’s largest companies are leveraging biotech to stay competitive, meet sustainability goals, and shape the future of industry.
[…]
May 5, 2026
Bio500: How the World's Biggest Companies are Transforming Their Value Chains with Biotech.
Fortune 500 companies are turning to synthetic biology to drive efficiency, resilience, and sustainability across their value chains. By integrating biotech, they can reduce reliance on scarce resources, accelerate product innovation, and respond to shifting consumer and regulatory demands. This session brings together leaders from global companies to share how biology is reshaping sourcing, production, and product portfolios. Attendees will gain insights into strategic approaches, cross-industry collaboration, and the investments enabling large-scale transformation, providing a glimpse into how the world’s largest companies are leveraging biotech to stay competitive, meet sustainability goals, and shape the future of industry.
[…]
4
May 5, 2026
AIxBIO Masterclass - Boltz
4
May 5, 2026
AIxBIO Masterclass - Boltz
May 5, 2026
AIxBIO Masterclass - Boltz
5
May 6, 2026
Reversing Brain Damage: Can Programmable Biology Heal the Mind?
What if brain damage—from strokes, neurodegeneration, or even aging itself—could be reversed? ARPA-H is launching an ambitious effort to make this vision real, catalyzing technologies that repair neural circuits, restore lost tissue, and recover cognition. In this interactive workshop, we’ll ask: What could be the role of programmable biology in healing the brain? Could engineered cells rebuild damaged regions? Could synthetic gene circuits guide regeneration? Could AI-designed therapies restore function after injury or decline? Participants will join ARPA-H leaders to explore these questions, identify high-risk, high-reward opportunities, and help shape the future of neurorepair powered by programmable biology.
[…]
5
May 6, 2026
Reversing Brain Damage: Can Programmable Biology Heal the Mind?
What if brain damage—from strokes, neurodegeneration, or even aging itself—could be reversed? ARPA-H is launching an ambitious effort to make this vision real, catalyzing technologies that repair neural circuits, restore lost tissue, and recover cognition. In this interactive workshop, we’ll ask: What could be the role of programmable biology in healing the brain? Could engineered cells rebuild damaged regions? Could synthetic gene circuits guide regeneration? Could AI-designed therapies restore function after injury or decline? Participants will join ARPA-H leaders to explore these questions, identify high-risk, high-reward opportunities, and help shape the future of neurorepair powered by programmable biology.
[…]
May 6, 2026
Reversing Brain Damage: Can Programmable Biology Heal the Mind?
What if brain damage—from strokes, neurodegeneration, or even aging itself—could be reversed? ARPA-H is launching an ambitious effort to make this vision real, catalyzing technologies that repair neural circuits, restore lost tissue, and recover cognition. In this interactive workshop, we’ll ask: What could be the role of programmable biology in healing the brain? Could engineered cells rebuild damaged regions? Could synthetic gene circuits guide regeneration? Could AI-designed therapies restore function after injury or decline? Participants will join ARPA-H leaders to explore these questions, identify high-risk, high-reward opportunities, and help shape the future of neurorepair powered by programmable biology.
[…]
6
May 6, 2026
Programmable Immunity: Engineering the Universal Antivenom
For over a century, antivenoms have relied on serum extraction from animals — a process that’s costly, inconsistent, and limited to specific snake species. Today, advances in synthetic biology and antibody engineering are pointing toward a different future: a universal antivenom capable of neutralizing toxins across the world’s deadliest snakes. This session dives into the science and story behind this breakthrough — from the man who endured more than 200 bites to generate a unique immune response, to the researchers using those antibodies to design broad-spectrum, recombinant therapies. Together, they’re charting the path from survival experiment to programmable immunity.
[…]
6
May 6, 2026
Programmable Immunity: Engineering the Universal Antivenom
For over a century, antivenoms have relied on serum extraction from animals — a process that’s costly, inconsistent, and limited to specific snake species. Today, advances in synthetic biology and antibody engineering are pointing toward a different future: a universal antivenom capable of neutralizing toxins across the world’s deadliest snakes. This session dives into the science and story behind this breakthrough — from the man who endured more than 200 bites to generate a unique immune response, to the researchers using those antibodies to design broad-spectrum, recombinant therapies. Together, they’re charting the path from survival experiment to programmable immunity.
[…]
May 6, 2026
Programmable Immunity: Engineering the Universal Antivenom
For over a century, antivenoms have relied on serum extraction from animals — a process that’s costly, inconsistent, and limited to specific snake species. Today, advances in synthetic biology and antibody engineering are pointing toward a different future: a universal antivenom capable of neutralizing toxins across the world’s deadliest snakes. This session dives into the science and story behind this breakthrough — from the man who endured more than 200 bites to generate a unique immune response, to the researchers using those antibodies to design broad-spectrum, recombinant therapies. Together, they’re charting the path from survival experiment to programmable immunity.
[…]
7
May 6, 2026
The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology (for Aclid Bio)
As AI, automation, and scalable biotechnologies accelerate the design and deployment of biology, the line between innovation and risk is increasingly blurred. This session explores how advances in programmable biology are reshaping biosecurity and biodefense, from dual-use risks and supply-chain vulnerabilities to new models for detection, governance, and defense. Leaders from industry, government, and research will discuss how to responsibly accelerate biology while protecting public health and national security.
[…]
7
May 6, 2026
The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology (for Aclid Bio)
As AI, automation, and scalable biotechnologies accelerate the design and deployment of biology, the line between innovation and risk is increasingly blurred. This session explores how advances in programmable biology are reshaping biosecurity and biodefense, from dual-use risks and supply-chain vulnerabilities to new models for detection, governance, and defense. Leaders from industry, government, and research will discuss how to responsibly accelerate biology while protecting public health and national security.
[…]
May 6, 2026
The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology (for Aclid Bio)
As AI, automation, and scalable biotechnologies accelerate the design and deployment of biology, the line between innovation and risk is increasingly blurred. This session explores how advances in programmable biology are reshaping biosecurity and biodefense, from dual-use risks and supply-chain vulnerabilities to new models for detection, governance, and defense. Leaders from industry, government, and research will discuss how to responsibly accelerate biology while protecting public health and national security.
[…]
8
May 6, 2026
The New Main Course: Cultured Meat + Precision Fermentation
Plant-based food sales may be slowing, but that doesn’t mean innovation on the plate is stalling. Instead, momentum is shifting toward breakthrough technologies and smarter ingredient combinations. Cultured meat and precision fermentation are driving the next wave of sustainable ingredients, from proteins to cultured fats that bring authentic flavor and texture. This session highlights advances in cell culture, fermentation platforms, and scale-up strategies, along with the partnerships moving products from R&D to dining tables. Hear how food innovators are combining biology and culinary creativity to build a resilient, delicious, and sustainable future for global diets.
[…]
8
May 6, 2026
The New Main Course: Cultured Meat + Precision Fermentation
Plant-based food sales may be slowing, but that doesn’t mean innovation on the plate is stalling. Instead, momentum is shifting toward breakthrough technologies and smarter ingredient combinations. Cultured meat and precision fermentation are driving the next wave of sustainable ingredients, from proteins to cultured fats that bring authentic flavor and texture. This session highlights advances in cell culture, fermentation platforms, and scale-up strategies, along with the partnerships moving products from R&D to dining tables. Hear how food innovators are combining biology and culinary creativity to build a resilient, delicious, and sustainable future for global diets.
[…]
May 6, 2026
The New Main Course: Cultured Meat + Precision Fermentation
Plant-based food sales may be slowing, but that doesn’t mean innovation on the plate is stalling. Instead, momentum is shifting toward breakthrough technologies and smarter ingredient combinations. Cultured meat and precision fermentation are driving the next wave of sustainable ingredients, from proteins to cultured fats that bring authentic flavor and texture. This session highlights advances in cell culture, fermentation platforms, and scale-up strategies, along with the partnerships moving products from R&D to dining tables. Hear how food innovators are combining biology and culinary creativity to build a resilient, delicious, and sustainable future for global diets.
[…]
9
May 5, 2026
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
[…]
9
May 5, 2026
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
[…]
May 5, 2026
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
[…]
10
May 5, 2026
Beyond Static Predictions — AI for Protein Dynamics and Multi-Cell Models
The next frontier of biology isn’t in predicting a single static protein structure, but in capturing how proteins move, fold, and interact across time and environments. This session explores how AI can illuminate protein conformations and dynamics, and extend those insights into virtual multi-cellular or tissue models. Experts will discuss the challenge of integrating heterogeneous datasets and instruments, and how breakthroughs in dynamic modeling could reshape drug design, disease understanding, and biomanufacturing. Can we build models that reflect the living, breathing complexity of biology—not just snapshots, but motion?
[…]
10
May 5, 2026
Beyond Static Predictions — AI for Protein Dynamics and Multi-Cell Models
The next frontier of biology isn’t in predicting a single static protein structure, but in capturing how proteins move, fold, and interact across time and environments. This session explores how AI can illuminate protein conformations and dynamics, and extend those insights into virtual multi-cellular or tissue models. Experts will discuss the challenge of integrating heterogeneous datasets and instruments, and how breakthroughs in dynamic modeling could reshape drug design, disease understanding, and biomanufacturing. Can we build models that reflect the living, breathing complexity of biology—not just snapshots, but motion?
[…]
May 5, 2026
Beyond Static Predictions — AI for Protein Dynamics and Multi-Cell Models
The next frontier of biology isn’t in predicting a single static protein structure, but in capturing how proteins move, fold, and interact across time and environments. This session explores how AI can illuminate protein conformations and dynamics, and extend those insights into virtual multi-cellular or tissue models. Experts will discuss the challenge of integrating heterogeneous datasets and instruments, and how breakthroughs in dynamic modeling could reshape drug design, disease understanding, and biomanufacturing. Can we build models that reflect the living, breathing complexity of biology—not just snapshots, but motion?
[…]
11
May 6, 2026
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
[…]
10
May 6, 2026
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
[…]
May 6, 2026
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
[…]
What Happens When The
Entire Industry Is Under One Roof
Startups, investors, global strategics, and technology providers come to San Jose to discover new partners, forge customer relationships, and accelerate the adoption of biology across every major industry.
When you sponsor or exhibit, you’re not just showing up — you’re shaping the conversations and deals that move biotechnology forward.



55%
Decision Makers
1180+
Companies
13%
Founders
2000+
Attendees
29%
C-Suite Level
8%
Directors
SynBioBeta conference experience

Join for the latest
SynBioBeta event updates.

Join for the latest SynBioBeta event updates.



















































































